AB0415 SURVIVAL OF BIOLOGIC AGENTS WITHIN A COHORT OF GREEK PATIENTS WITH RHEUMATOID ARTHRITIS. REAL WORLD DATA.

Olga Katsouli\(^1\), Georgia Liantinioti\(^1\), Panagiota Katsouli\(^2\), Mary Pappa\(^3\), Markos Patsouras\(^4\), Theodoros Angelopoulos\(^5\), Sotiris Roussos\(^6\).

VLACHOYIANNOPoulos PANAYIOTIS \(^1\) 1Medical School National and Kapodistrian University of Athens, Department of Pathophysiology, Athens, Greece; \(^2\) Medical School National and Kapodistrian University of Athens, Athens, Greece; \(^3\) Medical School National and Kapodistrian University of Athens, Hygiene, Epidemiology and Medical Statistics, Athens, Greece

Background: Rheumatoid arthritis (RA) is treated successfully with biologic disease-modifying anti-rheumatic drugs (bDMARDs). However, a significant withdrawal rate, due to non-responsiveness or toxicity, remains a major barrier for their long-term use.

Objectives: To determine the withdrawal rate of the first bDMARD in a large cohort of RA patients due either to non-responsiveness or toxicity.

Methods: In this study, we included retrospectively 220 patients from our outpatient clinic. The following bDMARDs were evaluated: Etanercept (n=46 patients), Adalimumab (n=61 patients), Infliximab (n=70 patients), Rituximab (n=6 patients) and others, such as Certolizumab pegol, Golimumab, Tocilizumab, Anakinra and Abatacept (n=17 patients). Disease activity was regularly measured by DAS-28 until the end of follow-up. Kaplan-Meier plots were performed to examine the withdrawal rate of each biologic agent. Seventy of AEs was classified according to the Common Terminology Criteria for Adverse Events (CTCAE, version 4.03).

Results: A total of 220 patients (49 men, 171 women) were included in the analysis. The most frequently used first-line bDMARDs were Infliximab (31.8%), Etanercept (30%) and Adalimumab (27.7%). The median of treatment duration with the first bDMARD was 15 months (Q1:8, Q3:40.5). Taking all bDMARDs as a whole, 126 patients (57.27%) discontinued due to failure of therapy (n=86, 52.38%), or loss of efficacy (n=60,47.62%) after a follow-up of 167 months. However the most withdrawals (53.18%) occurred within the first 60 months of follow-up. Mean initial and final DAS-28 were: for those who discontinued due to AEs (4.96±1.33(95%CI 4.6-5.28) and 3.43±1.47(95%CI, 3.08-3.79), respectively, for those who continued 4.79±1.55(95%CI, 4.47-5.10) and 2.63±1.06(95%CI, 2.41-2.84), respectively. Differences in survival among bDMARDs are attributed to their AEs and not to their efficacy. As far as the AEs are concerned, infections constituted the majority of cases (n=23, 34.8%), from which 34.8% needed hospitalization (CTCAE 3-4). The percentage of 12.1% of AEs is attributed to cancer cases, while allergic reactions counted for 31.8% of them. Survival of Etanercept within our cohort was significantly longer than that of other bDMARDs.

Conclusion: Biologic agents are important drugs in our armamentarium to combat RA. However nearly 50% of patients discontinue these agents after 60 months of treatment due either to AEs or inefficacy. Differences in survival of bDMARDs were associated not to their inefficacy, but to their AEs. Choosing the right drug for the right patient is a matter of advanced research involving a better understanding of the plasticity of the pathways of inflammation and specific biomarker selection.

REFERENCES
